Sarepta Therapeutics (SRPT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$17.73-2.48%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sarepta Therapeutics’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-55.6% · beyond scale

+10% or more+5%0%−5%−10% or less

0.78 → 0.34 EPS · FY ending Dec 31, 2027 · 11 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 11; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	351.35M
EPS	—	-0.061
Annual ending 2026-12-31
Revenue	—	1.84B
EPS	—	3.083
Annual ending 2027-12-31
Revenue	—	1.41B
EPS	—	0.344

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain non-GAAP R&D and SG&A expenses between $800M and $900M in 2026	A supporting condition in Sarepta Therapeutics's published investment case. The stated target is non-GAAP R&D and SG&A expenses between $800M and $900M.	Intact	expenses exceed $900 million in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management narrowed combined non-GAAP R&D and SG&A expense guidance from $800-$900 million to $800-$850 million for 2026. This reflects a focus on cost discipline. Actual expense figures for the first half of 2026 show decreases consistent with this guidance. The trajectory is delivering on cost control. Delivery assessment Oct 24, 2026
Smooth CEO transition by end of 2026	A supporting condition in Sarepta Therapeutics's published investment case. The stated target is CEO transition completed without disruption by end 2026.	Intact	CEO transition causes significant operational disruption or delays	CEO transition completed 2026-07-27 vs end-2026 target Executive change event confirms Dr. Michael Severino succeeded Douglas Ingram as CEO on July 27, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve profitability and cash-flow positivity in 2026	Sarepta aims to be profitable and cash-flow positive in 2026.	Broken	net income or cash flow turns negative in any quarter of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Sarepta delivered GAAP operating income of $358.4 million in 2026-Q1 and $13.3 million in 2026-Q2, with net income positive in Q1 but negative in Q2. Cash and equivalents increased from $748.3 million in Q1 to $945.0 million in Q2. Management is delivering profitability and cash flow positivity with some quarterly variability. Delivery assessment Oct 24, 2026
Reach revenue of about $1.3 billion in 2026	Revenue is guided to grow to about $1.3 billion in 2026.	Broken	annual revenue falls below $1.2 billion in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Sarepta delivered GAAP operating income of $358.4 million in 2026-Q1 and $13.3 million in 2026-Q2, with net income positive in Q1 but negative in Q2. Cash and equivalents increased from $748.3 million in Q1 to $945.0 million in Q2. Management is delivering profitability and cash flow positivity with some quarterly variability. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.34

$2.45 → $0.34 · observed estimates

FY2027 revenue$1.41B

$1.41B → $1.41B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.45	$1,408,535,950	11 / 19
2026-07-25	$2.45	$1,408,535,950	11 / 19
2026-07-26	$2.45	$1,408,535,950	11 / 19
2026-07-27	$0.86	$1,418,322,237	12 / 15
2026-07-28	$2.45	$1,408,535,950	11 / 19
2026-07-29	$2.45	$1,408,535,950	11 / 19
2026-07-30	$0.86	$1,418,322,237	11 / 15
2026-07-31	$0.86	$1,418,322,237	11 / 15
2026-08-01	$0.86	$1,418,322,237	11 / 15
2026-08-02	$2.45	$1,408,535,950	11 / 19
2026-08-03	$2.45	$1,408,535,950	11 / 19
2026-08-04	$2.45	$1,408,535,950	11 / 19
2026-08-05	$0.86	$1,418,322,237	11 / 15
2026-08-06	$0.86	$1,418,322,237	11 / 15
2026-08-08	$2.87	$1,391,154,100	10 / 19
2026-08-09	$0.76	$1,414,342,245	11 / 15
2026-08-10	$2.60	$1,389,680,420	11 / 19
2026-08-12	$0.76	$1,414,342,245	11 / 15
2026-08-13	$0.76	$1,414,342,245	11 / 15
2026-08-14	$0.76	$1,414,342,245	11 / 15
2026-08-15	$0.76	$1,414,342,245	11 / 15
2026-08-16	$0.76	$1,414,342,245	11 / 15
2026-08-17	$0.76	$1,414,342,245	11 / 15
2026-08-18	$0.76	$1,414,342,245	11 / 15
2026-08-19	$0.76	$1,414,342,245	11 / 15
2026-08-20	$0.75	$1,401,132,113	11 / 15
2026-08-21	$0.75	$1,401,132,113	11 / 15
2026-08-22	$0.75	$1,401,132,113	11 / 15
2026-08-23	$0.75	$1,401,132,113	11 / 15
2026-08-24	$0.75	$1,401,132,113	11 / 15
2026-08-25	$0.65	$1,393,358,077	11 / 15
2026-08-26	$0.65	$1,393,358,077	11 / 15
2026-08-27	$0.65	$1,393,358,077	11 / 15
2026-08-28	$0.75	$1,405,205,437	11 / 15
2026-08-29	$0.75	$1,405,205,437	11 / 15
2026-08-30	$0.75	$1,405,205,437	11 / 15
2026-08-31	$0.75	$1,405,205,437	11 / 15
2026-09-01	$0.75	$1,405,205,437	11 / 15
2026-09-02	$0.75	$1,405,205,437	11 / 15
2026-09-03	$0.75	$1,405,205,437	11 / 15
2026-09-04	$0.75	$1,405,205,437	11 / 15
2026-09-05	$0.75	$1,405,205,437	11 / 15
2026-09-06	$0.75	$1,405,205,437	11 / 15
2026-09-07	$0.75	$1,405,205,437	11 / 15
2026-09-08	$0.75	$1,405,205,437	11 / 15
2026-09-09	$0.75	$1,405,205,437	11 / 15
2026-09-10	$0.75	$1,405,205,437	11 / 15
2026-09-11	$0.75	$1,405,205,437	11 / 15
2026-09-12	$0.75	$1,405,205,437	11 / 15
2026-09-13	$0.75	$1,405,205,437	11 / 15
2026-09-14	$0.75	$1,405,205,437	11 / 15
2026-09-15	$0.75	$1,405,205,437	11 / 15
2026-09-16	$0.75	$1,405,205,437	11 / 15
2026-09-17	$0.78	$1,409,339,029	11 / 14
2026-09-18	$0.78	$1,409,339,029	11 / 14
2026-09-19	$0.78	$1,409,339,029	11 / 14
2026-09-20	$0.78	$1,409,339,029	11 / 14
2026-09-21	$0.78	$1,409,339,029	11 / 14
2026-09-22	$0.78	$1,409,339,029	11 / 14
2026-09-23	$0.78	$1,409,339,029	11 / 14
2026-09-24	$0.78	$1,409,339,029	11 / 14
2026-09-25	$0.78	$1,409,339,029	11 / 14
2026-09-26	$0.78	$1,409,339,029	11 / 14
2026-09-27	$0.78	$1,409,339,029	11 / 14
2026-09-28	$0.78	$1,409,339,029	11 / 14
2026-09-29	$0.78	$1,409,339,029	11 / 14
2026-09-30	$0.65	$1,404,925,983	11 / 15
2026-10-01	$0.65	$1,404,925,983	11 / 15
2026-10-02	$0.55	$1,405,319,758	11 / 15
2026-10-03	$0.55	$1,405,319,758	11 / 15
2026-10-04	$0.55	$1,405,321,349	11 / 15
2026-10-05	$0.55	$1,405,321,349	11 / 15
2026-10-06	$0.55	$1,405,321,349	11 / 15
2026-10-07	$0.55	$1,405,321,349	11 / 15
2026-10-08	$0.55	$1,405,321,349	11 / 15
2026-10-09	$0.55	$1,405,316,803	11 / 15
2026-10-10	$0.53	$1,405,416,803	11 / 15
2026-10-11	$0.53	$1,403,094,084	11 / 15
2026-10-12	$0.53	$1,403,094,084	11 / 15
2026-10-13	$0.53	$1,403,094,084	11 / 15
2026-10-14	$0.49	$1,403,777,565	11 / 15
2026-10-15	$0.49	$1,403,777,565	11 / 15
2026-10-16	$0.51	$1,405,832,111	11 / 15
2026-10-17	$0.51	$1,405,832,111	11 / 15
2026-10-18	$0.51	$1,405,832,111	11 / 15
2026-10-19	$0.51	$1,405,832,111	11 / 15
2026-10-20	$0.51	$1,405,832,111	11 / 15
2026-10-21	$0.51	$1,405,832,111	11 / 15
2026-10-22	$0.34	$1,405,832,111	11 / 15
2026-10-23	$0.34	$1,405,832,111	11 / 15
2026-10-24	$0.34	$1,405,832,111	11 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	13	5
2026-06-01	7	13	5
2026-07-01	8	13	5
2026-08-01	8	11	5
2026-09-01	8	12	5
2026-10-01	7	12	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 12 Hold · 5 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 8

$17.00New observation · no comparable prior

$0$9.35$18.70

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain non-GAAP R&D and SG&A expenses between $800M and $900M in 2026Direct metric needs a verified mapping
Achieve profitability and cash-flow positivity in 2026Published status: Broken
Reach revenue of about $1.3 billion in 2026Published status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-39.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sarepta Therapeutics outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

SRPT is a high-risk biotechnology company with commercial products and a developing siRNA pipeline. Its multi-year view is intact, while recent financial performance is strong and management execution is on track but volatile.

What's priced into Sarepta Therapeutics

The valuation evidence points to SRPT being cheap versus peers, with a low-confidence model and a negative expectations gap. The evidence tags current pricing as justified and shows no fragility flags, so the apparent peer discount does not by itself establish that expectations are undemanding.

What the fundamentals likely do

Near term, product revenue has been stable across the first two quarters of 2026, and management has narrowed its expense guidance while advancing the pipeline. Profitability has varied by quarter, and an estimated 47% miss probability, erratic earnings surprises, litigation, and a recent CEO transition add uncertainty around the next results. Over the multi-year view, execution depends on sustaining commercial performance and turning pipeline progress into further evidence of business strength.

What Sarepta Therapeutics hinges on

The next call is an important swing factor: a guidance cut would weaken the near-term picture. Ongoing clinical readouts and continued delivery on costs and cash flow matter to the multi-year thesis. Healthcare sector momentum could support the backdrop, while weaker jobs data may increase recession concerns.